• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

    5/13/25 4:11:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mauro Garry Paul

    (Last) (First) (Middle)
    3300 TRIUMPH BLVD, SUITE 700

    (Street)
    LEHI UT 84043

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Lifevantage Corp [ LFVN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/09/2025 P 601 A $12.25 86,087 D
    Common Stock 05/09/2025 P 298 A $12.25 33,152 I By The Dominic C. Mauro Trust of 2021
    Common Stock 05/09/2025 P 298 A $12.25 33,152 I By The Andrew H. Mauro Trust of 2021
    Common Stock 05/09/2025 P 298 A $12.25 33,152 I By The Francesco A. Mauro Trust of 2021
    Common Stock 05/09/2025 P 298 A $12.25 32,840 I By The David W.B. Mauro Trust of 2021
    Common Stock 05/09/2025 P 298 A $12.25 32,840 I By The Alexandra P. Mauro Trust of 2021
    Common Stock 05/09/2025 P 59 A $12.25 6,598 I By Garry Paul Mauro SEP IRA
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Alissa Neufeld, Power of Attorney for Garry P. Mauro 05/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LFVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,618 worth of shares (351 units at $10.31), increasing direct ownership by 0.33% to 108,342 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      9/17/24 6:20:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Convention 2025 Empowers Consultants to 'Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth

      SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed

      4/28/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

      SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

      1/16/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

      SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

      8/26/24 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

      SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e

      7/22/24 6:27:51 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      7/31/24 8:07:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:29:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:27:16 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Financials

    Live finance-specific insights

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025

      SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after th

      4/22/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    SEC Filings

    See more
    • Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:06:34 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:05:28 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      2/5/25 4:05:56 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 3,659 shares, decreasing direct ownership by 3% to 104,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      4/30/25 4:23:59 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Fife Steven R covered exercise/tax liability with 21,089 shares, decreasing direct ownership by 3% to 632,371 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      4/3/25 6:06:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care